April 25th 2025
Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.
Biosimilar Utilization Increased During the OCM and Generated Savings
June 23rd 2022Abstracts presented at the American Society of Clinical Oncology Annual Meeting evaluated biosimilar use in practices participating in the Oncology Care Model (OCM) and estimated the savings as a result of substituting these agents for more expensive reference products.
Read More
There Is More to Blame Than Tech for T1D Outcomes Disparities, Investigators Argue
June 21st 2022Investigators from the Pediatric Diabetes Center at Hassenfeld Children’s Hospital at NYU Langone investigated outcomes disparities as they related to diabetes technology use among youth living with type 1 diabetes (T1D).
Read More
Standard-of-Care Treatments Insufficient in Improving QOL for Patients With Multiple Myeloma
June 19th 2022Patients with multiple myeloma frequently relapse and experience deteriorating quality of life, according to findings from the LocoMMotion study, which also reported that specific patient and disease characteristics are associated with poor efficacy outcomes.
Read More
Sacubitril/Valsartan Safe, Effective Among CHF Patients on Maintenance Hemodialysis
June 18th 2022Outcomes in this new study, conducted among patients with chronic heart failure (CHF) on maintenance dialysis and receiving sacubitril/valsartan, were evaluated as they pertained to heart function and blood pressure.
Read More
Caregiver Contributions in Heart Failure Require Further Study
June 16th 2022The primary outcomes of this secondary analysis of the MOTIVATE-HF study were improvement in caregiver self-efficacy while caring for patients living with heart failure and caregiver contributions to self-care for these patients following motivational interviewing.
Read More
Dr Mazyar Shadman Highlights the Challenges of Subgroup Analysis When Trials Lack Diversity
June 16th 2022Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at outcomes for specific races, age groups or genders, said Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center.
Watch
Survivors of Childhood Cancer More Likely to Be Undertreated for CVD Risk Factors
June 11th 2022Despite a greater risk of cardiovascular disease (CVD) due to exposure to chemotherapy and/or radiation, adult survivors of childhood cancer are undertreated for CVD risk factors compared with the general population.
Read More
Dr Constantine Tam Discusses Impact of Public Funding for BTK Inhibitor Use in R/R CLL
June 10th 2022Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, explains findings of his abstract at EHA2022 showing the impact of Australia’s pharmaceuticals benefit scheme on the rise of Bruton tyrosine kinase (BTK) inhibitor prescriptions for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL), as well as reasons behind the decrease in fludarabine, cyclophosphamide, and rituximab combination therapy usage for first-line CLL.
Watch
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center and University of Washington, discussed positive health-related quality of life (HRQOL) findings of the SEQUOIA trial investigating zanubrutinib vs bendamustine/rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Watch
CREATE Trial Data Add to Support of Open-Source AID Use in T1D
June 9th 2022Findings presented at the 82nd Scientific Sessions of the American Diabetes Association support the safety and efficacy of open-source automated insulin delivery (AID) systems among children and adults living with type 1 diabetes (T1D).
Read More